A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Gastric Cancer
Interventions: DRUG: Capecitabine|DRUG: Trastuzumab emtansine (T-DM1)|DRUG: Trastuzumab emtansine (T-DM1)|DRUG: Capecitabine
Sponsor: Hoffmann-La Roche